Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Double-Crane Pharmaceutical Co's quarterly Ending Cash Position
increased
from Dec. 2025 (¥1,908 Mil) to Mar. 2026 (¥2,566 Mil) and
increased
from Mar. 2026 (¥2,566 Mil) to Jun. 2026 (¥2,770 Mil).
China Resources Double-Crane Pharmaceutical Co's annual Ending Cash Position
declined
from Dec. 2023 (¥3,208 Mil) to Dec. 2024 (¥2,838 Mil) and
declined
from Dec. 2024 (¥2,838 Mil) to Dec. 2025 (¥1,908 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Ending Cash Position Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
China Resources Double-Crane Pharmaceutical Co Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
What does a Ending Cash Position of ¥2,770 Mil mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Ending Cash Position of ¥2,770 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors.
Is China Resources Double-Crane Pharmaceutical Co's Ending Cash Position too high?
China Resources Double-Crane Pharmaceutical Co's current Ending Cash Position is ¥2,770 Mil. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Ending Cash Position compare to ZTS?
China Resources Double-Crane Pharmaceutical Co's Ending Cash Position of ¥2,770 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. China Resources Double-Crane Pharmaceutical Co's current Ending Cash Position is ¥2,770 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.76, compared to a current price of ¥15.97 — trading 14.9% below its estimated fair value. The current Ending Cash Position is ¥2,770 Mil. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Ending Cash Position is ¥2,770 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥15.97 is trading 14.9% below its estimated GF Value™ of ¥18.76.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Ending Cash Position: ¥2,770 Mil
GF Value™: ¥18.76 vs. price of ¥15.97 (14.9% below fair value)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
91GF Score
Get the complete analysis for SHSE:600062
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
